Peripheral T Cell Lymphoma Clinical Trials
4 recruiting trials for Peripheral T Cell Lymphoma. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Peripheral T Cell Lymphoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Early Phase 1 is the largest group at 33% (1 studies); the largest phase groups are Early Phase 1: 1, Phase 3: 1, Phase 1 / Phase 2: 1.
Research is led by New York Medical College (1), Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1), Acrotech Biopharma Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Methotrexate (drug, 1 trial), followed by pralatraxate,, Ifosfamide.
Track Peripheral T Cell Lymphoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in...
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the observation group and the autologous hematopoietic stem cell transplantation group...
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL...
Evaluate the Safety and Clinical Activity of HH2853
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Peripheral T Cell Lymphoma, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Peripheral T Cell Lymphoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Peripheral T Cell Lymphoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.